Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT05433376
Other study ID # GM-PI-CIP001
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date April 15, 2021
Est. completion date November 26, 2022

Study information

Verified date June 2022
Source Genesis Medtech Corporation
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a small sample size clinical trial in Chinese population to assess the safety and effectiveness of the Shockwave Coronary Intravascular Lithotripsy (IVL) System to treat de novo, calcified, stenotic, coronary lesions prior to stenting.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 20
Est. completion date November 26, 2022
Est. primary completion date November 25, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: General 1. Subject =18 and =80 years of age,male or female. 2. Subjects with native coronary artery disease (including stable or unstable angina and silent ischemia) suitable for PCI 3. Subject or legally authorized representative, signs a written Informed Consent form to participate in the study, prior to any study-mandated procedures Angiographic 4. Evidence of calcification at the lesion site by, a) angiography, with fluoroscopic radio-opacities noted without cardiac motion prior to contrast injection involving both sides of the arterial wall in at least one location and total length of calcium of at least 15 mm and extending partially into the target lesion, OR by b) OCT, with presence of =270 degrees of calcium on at least 1 cross section 5. The lesion length must not exceed 40 mm 6. The target vessel reference diameter must be =2.5 mm and =4.0 mm 7. de novo target lesion stenosis of protected LMCA, or LAD, RCA or LCX (or of their branches), per investigator's assessment with: 1. Stenosis of =70% and <100% or 2. Stenosis =50% and <70% (visually assessed) that is deemed qualified for PCI by investigator 8. The target vessel must have TIMI flow 3 at baseline (visually assessed; may be assessed after pre-dilatation) 9. Ability to pass a 0.014" guide wire across the lesion Exclusion Criteria: General 1. Any comorbidity or condition which may reduce compliance with this protocol, including follow-up visits 2. Subject experienced an acute MI (STEMI or non-STEMI) within 30 days prior to index procedure 3. Subjects with cardiogenic shock or acute left heart failure; New York Heart Association (NYHA) class III or IV heart failure; left ventricular ejection fraction (LVEF) = 35% within 6 months prior to the procedure (Note: if multiple LVEF assessments were performed, the measurement closest to index procedure will be chosen; it can be assessed in the procedure); 4. History of a stroke or transient ischemic attack (TIA) within 6 months, or any prior intracranial hemorrhage or permanent neurologic deficit 5. Uncontrolled diabetes defined as a HbA1c =10% 6. Non-coronary interventional or surgical structural heart procedures (e.g., TAVR, MitraClip, LAA or PFO occlusion, etc.) within 30 days prior to the index procedure 7. Subject refusing or not a candidate for emergency coronary artery bypass grafting (CABG) surgery 8. Uncontrolled severe hypertension (systolic BP >180 mm Hg or diastolic BP >110 mm Hg) 9. Subject is participating in another research study involving an investigational agent (pharmaceutical, biologic, or medical device) that has not reached the primary endpoint 10. Subject is pregnant or nursing (a negative pregnancy test is required for women of child-bearing potential within 7 days prior to enrollment); Or plans to become pregnant within 13 months after the study procedure; 11. Unable to tolerate dual antiplatelet therapy (i.e., aspirin, and either clopidogrel, prasugrel, or ticagrelor) for at least 6 months (for patients not on oral anticoagulation) 12. Subject has an allergy to imaging contrast media which cannot be adequately pre-medicated 13. Renal failure with serum creatinine >2.5 mg/dL or chronic dialysis 14. Active peptic ulcer or upper gastrointestinal (GI) bleeding within 6 months 15. Untreated pre-procedural hemoglobin <10 g/dL or intention to refuse blood transfusions if one should become necessary 16. Coagulopathy, including but not limited to platelet count <100,000 or International Normalized ratio (INR) > 1.7 (INR is only required in subjects who have taken warfarin within 2 weeks of enrollment) 17. Subject has a hypercoagulable disorder such as polycythemia vera, platelet count >750,000 or other disorders 18. Biomarkers [troponin or CK-MB] greater than the upper laboratory normal limit within 72 hours prior to index procedure (note: if both biomarkers are available, both must be normal) 19. Subject has an active systemic infection on the day of the index procedure with either fever, leukocytosis or requiring intravenous antibiotics 20. Subjects with a life expectancy of less than 1 year 21. Planned use of atherectomy, laser or scoring or cutting balloon, or any investigational device other than lithotripsy Angiographic 22. Previous stent within the target vessel implanted within the last year 23. Previous stent within 10 mm of the target lesion regardless of the timing of its implantation 24. Angiographic evidence of a dissection (= grade C) in the target vessel at baseline or after guidewire passage 25. Lesions in non-target vessels requiring PCI as below should be excluded: 1. 24 hours to 30 days prior to the study procedure if the procedure was unsuccessful or complicated; or 2. In 24 hours prior to the study procedure 3. >30 days after the study procedure 26. Non-target lesion is including left main lesion with diameter stenosis =30% 27. Target vessel is too tortuous to deliver a stent assessed by investigators. 28. Definite or possible thrombus (by angiography or intravascular imaging) in the target vessel 29. Evidence of aneurysm in target vessel within 10 mm of the target lesion 30. Target lesion is an ostial location (LAD, LCX, or RCA, within 5 mm of ostium) or an unprotected left main lesion. 31. Target lesion is a bifurcation with ostial diameter stenosis =30% 32. Second lesion with >50% stenosis in the same target vessel as the target lesion including its side branches 33. Target lesion is located in a native vessel that can only be reached by going through a saphenous vein or arterial bypass graft 34. Other situations not suitable for enrollment assessed by investigators.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Shockwave Coronary Intravascular Lithotripsy (IVL) System C2
lithotripsy-enabled, low-pressure dilatation balloon to modify severely calcified lesions

Locations

Country Name City State
China Beijing Anzhen Hospital,Capital Medical University Beijing
China Beijing Friendship Hospital,Capital Medical University Beijing
China Chinese Peoples Liberation Army General Hospital Beijing

Sponsors (1)

Lead Sponsor Collaborator
Genesis Medtech Corporation

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Procedural Success defined as stent delivery with a residual stenosis <50% (core laboratory assessed, angiographically) and without in-hospital MACE in 24 hours post-procedure or prior to discharge, whichever comes first
Primary Freedom from major adverse cardiac events (MACE) within 30 days of the index procedure. MACE is defined as:
Cardiac death; or
Myocardial Infarction (MI) defined as CK-MB level > 3 times the upper limit of lab normal (ULN) value with or without new pathologic Q wave at discharge (periprocedural MI) and using the Fourth Universal Definition of Myocardial Infarction beyond discharge (spontaneous MI); or
Target Vessel Revascularization (TVR) defined as revascularization at the target vessel (inclusive of the target lesion) after the completion of the index procedure
30 days post index procedure
See also
  Status Clinical Trial Phase
Recruiting NCT06030596 - SPECT Myocardial Blood Flow Quantification for Diagnosis of Ischemic Heart Disease Determined by Fraction Flow Reserve
Completed NCT04080700 - Korean Prospective Registry for Evaluating the Safety and Efficacy of Distal Radial Approach (KODRA)
Recruiting NCT03810599 - Patient-reported Outcomes in the Bergen Early Cardiac Rehabilitation Study N/A
Recruiting NCT06002932 - Comparison of PROVISIONal 1-stent Strategy With DEB Versus Planned 2-stent Strategy in Coronary Bifurcation Lesions. N/A
Not yet recruiting NCT06032572 - Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE) N/A
Recruiting NCT04242134 - Drug-coating Balloon Angioplasties for True Coronary Bifurcation Lesions N/A
Recruiting NCT05308719 - Nasal Oxygen Therapy After Cardiac Surgery N/A
Completed NCT04556994 - Phase 1 Cardiac Rehabilitation With and Without Lower Limb Paddling Effects in Post CABG Patients. N/A
Recruiting NCT05846893 - Drug-Coated Balloon vs. Drug-Eluting Stent for Clinical Outcomes in Patients With Large Coronary Artery Disease N/A
Recruiting NCT06027788 - CTSN Embolic Protection Trial N/A
Recruiting NCT05023629 - STunning After Balloon Occlusion N/A
Completed NCT04941560 - Assessing the Association Between Multi-dimension Facial Characteristics and Coronary Artery Diseases
Completed NCT04006288 - Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease Phase 4
Completed NCT01860274 - Meshed Vein Graft Patency Trial - VEST N/A
Recruiting NCT06174090 - The Effect of Video Education on Pain, Anxiety and Knowledge Levels of Coronary Bypass Graft Surgery Patients N/A
Completed NCT03968809 - Role of Cardioflux in Predicting Coronary Artery Disease (CAD) Outcomes
Terminated NCT03959072 - Cardiac Cath Lab Staff Radiation Exposure
Recruiting NCT05065073 - Iso-Osmolar vs. Low-Osmolar Contrast Agents for Optical Coherence Tomography Phase 4
Recruiting NCT04566497 - Assessment of Adverse Outcome in Asymptomatic Patients With Prior Coronary Revascularization Who Have a Systematic Stress Testing Strategy Or a Non-testing Strategy During Long-term Follow-up. N/A
Completed NCT05096442 - Compare the Safety and Efficacy of Genoss® DCB and SeQuent® Please NEO in Korean Patients With Coronary De Novo Lesions N/A